Dr. Janis Naeve, Ph.D. serves as Managing Director and Managing Partner at Amgen Ventures. Ms. Naeve joined Amgen Ventures of DecImmune Therapeutics, Inc. in 2005 and directs its investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. She served as the Director of Corporate Development of X-Ceptor Therapeutics from 2002 to 2005.
Dr. Naeve served as a Director of Business Development at Aurora Biosciences, where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly, and Bristol Myers-Squibb. She serves as a Board Observer of VLST Corporation. She serves as a Director of Acylin Therapeutics, Inc. Dr. Naeve serves as a Director at Oncofactor Corporation, Groove Biopharma Corporation, and REN Pharmaceuticals, Inc.
She has been a Director at NexImmune, Inc. since July 17, 2014. Dr. Naeve served an Executive Director at the Amgen Ventures. She served as a Director at Amgen Ventures. She served as a Director of Accelerator Corporation. She has a Ph.D. in Pathology from University of Southern California and completed a Post-Doctoral Fellowship at the California Institute of Technology.
Fund's investment verticals: biotechnology companies focused on human therapeutics, oncology, inflammation, hematology, metabolic disorders and cardiovascular diseases